ADAM33 and asthma: Asthma patients with persistent airflow limitation showed higher airway and systemic biomarkers of T2 inflammation (e.g., blood and BAL eosinophilia and circulating periostin), increased blood neutrophil counts, and serum concentration of ADAM-33.